Src as a potential therapeutic target in non-small-cell lung cancer

G. Giaccone, P. A. Zucali

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

Lung cancer is the most common cause of cancer-related death, with non-small-cell lung cancer (NSCLC) accounting for 80%-85% of all cases. Although survival rates are reasonably good for patients diagnosed with very early disease, the majority of patients present with advanced disease. For these patients, palliation and improvements in quality of life are the primary goals of therapy. Although chemotherapeutic agents remain the cornerstone of first-line therapy, these agents have limited use in patients who have relapsed and have metastatic disease. Therefore, new strategies are required to improve survival and quality of life in this setting. With the substantial advances in our understanding of tumour biology, it has been possible to identify signalling pathways involved in mediating tumour growth and progression. These pathways offer targets for new biological agents such as small molecule inhibitors and monoclonal antibodies. One such target is Src, a tyrosine kinase that is involved in multiple aspects of tumorigenesis including proliferation, migration and angiogenesis. Increased levels of Src expression have been found in a range of cancers, especially breast, colorectal, prostate and lung. Preliminary preclinical data and pharmacodynamic data suggest that Src inhibition is a viable therapeutic option in the treatment of advanced NSCLC.

Original languageEnglish
Pages (from-to)1219-1223
Number of pages5
JournalAnnals of Oncology
Volume19
Issue number7
DOIs
Publication statusPublished - Jul 2008

Fingerprint

Non-Small Cell Lung Carcinoma
Quality of Life
Neoplasms
src-Family Kinases
Biological Factors
Therapeutics
Prostate
Lung Neoplasms
Carcinogenesis
Survival Rate
Monoclonal Antibodies
Breast Neoplasms
Lung
Survival
Growth

Keywords

  • Non-small cell lung cancer
  • Src
  • Targeted therapy
  • Tyrosine kinase

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Src as a potential therapeutic target in non-small-cell lung cancer. / Giaccone, G.; Zucali, P. A.

In: Annals of Oncology, Vol. 19, No. 7, 07.2008, p. 1219-1223.

Research output: Contribution to journalArticle

@article{e0d78c5d1c3d4f5c84ffb3e0478ee70d,
title = "Src as a potential therapeutic target in non-small-cell lung cancer",
abstract = "Lung cancer is the most common cause of cancer-related death, with non-small-cell lung cancer (NSCLC) accounting for 80{\%}-85{\%} of all cases. Although survival rates are reasonably good for patients diagnosed with very early disease, the majority of patients present with advanced disease. For these patients, palliation and improvements in quality of life are the primary goals of therapy. Although chemotherapeutic agents remain the cornerstone of first-line therapy, these agents have limited use in patients who have relapsed and have metastatic disease. Therefore, new strategies are required to improve survival and quality of life in this setting. With the substantial advances in our understanding of tumour biology, it has been possible to identify signalling pathways involved in mediating tumour growth and progression. These pathways offer targets for new biological agents such as small molecule inhibitors and monoclonal antibodies. One such target is Src, a tyrosine kinase that is involved in multiple aspects of tumorigenesis including proliferation, migration and angiogenesis. Increased levels of Src expression have been found in a range of cancers, especially breast, colorectal, prostate and lung. Preliminary preclinical data and pharmacodynamic data suggest that Src inhibition is a viable therapeutic option in the treatment of advanced NSCLC.",
keywords = "Non-small cell lung cancer, Src, Targeted therapy, Tyrosine kinase",
author = "G. Giaccone and Zucali, {P. A.}",
year = "2008",
month = "7",
doi = "10.1093/annonc/mdn048",
language = "English",
volume = "19",
pages = "1219--1223",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "NLM (Medline)",
number = "7",

}

TY - JOUR

T1 - Src as a potential therapeutic target in non-small-cell lung cancer

AU - Giaccone, G.

AU - Zucali, P. A.

PY - 2008/7

Y1 - 2008/7

N2 - Lung cancer is the most common cause of cancer-related death, with non-small-cell lung cancer (NSCLC) accounting for 80%-85% of all cases. Although survival rates are reasonably good for patients diagnosed with very early disease, the majority of patients present with advanced disease. For these patients, palliation and improvements in quality of life are the primary goals of therapy. Although chemotherapeutic agents remain the cornerstone of first-line therapy, these agents have limited use in patients who have relapsed and have metastatic disease. Therefore, new strategies are required to improve survival and quality of life in this setting. With the substantial advances in our understanding of tumour biology, it has been possible to identify signalling pathways involved in mediating tumour growth and progression. These pathways offer targets for new biological agents such as small molecule inhibitors and monoclonal antibodies. One such target is Src, a tyrosine kinase that is involved in multiple aspects of tumorigenesis including proliferation, migration and angiogenesis. Increased levels of Src expression have been found in a range of cancers, especially breast, colorectal, prostate and lung. Preliminary preclinical data and pharmacodynamic data suggest that Src inhibition is a viable therapeutic option in the treatment of advanced NSCLC.

AB - Lung cancer is the most common cause of cancer-related death, with non-small-cell lung cancer (NSCLC) accounting for 80%-85% of all cases. Although survival rates are reasonably good for patients diagnosed with very early disease, the majority of patients present with advanced disease. For these patients, palliation and improvements in quality of life are the primary goals of therapy. Although chemotherapeutic agents remain the cornerstone of first-line therapy, these agents have limited use in patients who have relapsed and have metastatic disease. Therefore, new strategies are required to improve survival and quality of life in this setting. With the substantial advances in our understanding of tumour biology, it has been possible to identify signalling pathways involved in mediating tumour growth and progression. These pathways offer targets for new biological agents such as small molecule inhibitors and monoclonal antibodies. One such target is Src, a tyrosine kinase that is involved in multiple aspects of tumorigenesis including proliferation, migration and angiogenesis. Increased levels of Src expression have been found in a range of cancers, especially breast, colorectal, prostate and lung. Preliminary preclinical data and pharmacodynamic data suggest that Src inhibition is a viable therapeutic option in the treatment of advanced NSCLC.

KW - Non-small cell lung cancer

KW - Src

KW - Targeted therapy

KW - Tyrosine kinase

UR - http://www.scopus.com/inward/record.url?scp=46249085203&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=46249085203&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdn048

DO - 10.1093/annonc/mdn048

M3 - Article

C2 - 18388349

AN - SCOPUS:46249085203

VL - 19

SP - 1219

EP - 1223

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 7

ER -